SCHEMBL3454074

SCHEMBL3454074

NN1Oc2ccccc2CC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.43
MAOB P27338 1/20 0.43
HPGD P15428 2/20 0.38
RNASEH1 O60930 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2A6 P11509 1/20 0.36
GAA P10253 3/20 0.36
TLR9 Q9NR96 2/20 0.36
PKM P14618 1/20 0.36
NOTUM Q6P988 1/20 0.36
KMT2A Q03164 5/20 0.34
MEN1 O00255 3/20 0.34
ALDH1A1 P00352 3/20 0.33
CASP6 P55212 2/20 0.33
APAF1 O14727 2/20 0.33
MAPT P10636 2/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29844677 1.00 MAOA (0.43) MAOAMAOBHPGDRNASEH1CYP1A2
SCHEMBL7356037 0.77 MAOA (0.43) MAOAMAOBHPGDRNASEH1CYP1A2
SCHEMBL3239868 0.74 HPGD (0.47) MAOAMAOBHPGDRNASEH1CYP1A2
SCHEMBL29191977 0.73 MAOA (0.39) MAOAMAOBHPGDRNASEH1CYP1A2
SCHEMBL6527783 0.72 CASP6 (0.50) MAOAMAOBHPGDRNASEH1CYP1A2
SCHEMBL8088588 0.70 ALDH1A1 (0.39) MAOAMAOBHPGDRNASEH1CYP2A6
SCHEMBL7438103 0.69 MEN1 (0.39) MAOAMAOBHPGDRNASEH1GAA
SCHEMBL8580844 0.68 MAOB (0.39) MAOAMAOBHPGDRNASEH1CYP2A6
SCHEMBL7334246 0.68 CYP1A2 (0.45) MAOAMAOBCYP1A2CYP2A6NOTUM
SCHEMBL6645559 0.67 MAOA (0.39) MAOAMAOBHPGDGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776853-B2 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2010-08-17 US disclosed
EP-1631272-A4 METHODS OF TREATING OBESITY AND RELATED DISORDERS USING TELLURIUM AND SELENIUM COMPOUNDS RUBINSTEIN MENACHEM (IL) 2009-01-07 EP disclosed
EP-1255742-B1 2-THIO-4H-3,1-BENZOXAZIN-4-ONE DERIVATIVES FOR USE AS ENZYME INHIBITORS ALIZYME THERAPEUTICS LTD (GB) 2008-12-17 EP disclosed
US-20060166957-A1 Methods of treating obesity and related disorders using tellurium selenium compounds BIOMAS LTD. (IL) 2006-07-27 US disclosed
EP-1631272-A2 METHODS OF TREATING OBESITY AND RELATED DISORDERS USING TELLURIUM AND SELENIUM COMPOUNDS Rubinstein, Menachem (IL) 2006-03-08 EP disclosed
US-6916808-B2 2-thio-4h-3, 1-benzoxazin-4-one derivatives for use as enzyme inhibitors ALIZYME THERAPEUTICS LIMITED (GB) 2005-07-12 US disclosed
US-20050032795-A1 2-Amino-benzoxazinones for the treatment of herpes simplex virus G.D. SEARLE & CO. (US) 2005-02-10 US disclosed
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. (US) 2005-02-10 US disclosed
WO-2004110338-A2 METHODS OF TREATING OBESITY AND RELATED DISORDERS USING TELLURIUM AND SELENIUM COMPOUNDS BIOMAS LTD. (IL) 2004-12-23 WO disclosed
US-6806269-B1 EFFECTIVE AT LOWER CONCENTRATIONS; SUCH AS 6-(((1,1-DIMETHYL-ETHOXY)CARBONYL)AMINO)-5-METHYL-2-(METHYL(PHENYLMETHYL) -AMINO)-4H-3,1-BENZOXAZIN-4-ONE G. D. SEARLE & COP 2004-10-19 US disclosed
US-20030013707-A1 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2003-01-16 US disclosed
EP-1255742-A1 2-THIO-4H-3,1-BENZOXAZIN-4-ONE DERIVATIVES FOR USE AS ENZYME INHIBITORS Alizyme Therapeutics Limited (GB) 2002-11-13 EP disclosed
US-6380189-B1 FOR TREATING HERPES-RELATED DISORDERS G.D. SEARLE & CO. 2002-04-30 US disclosed
EP-1122245-A3 2-Amino-benzoxazinones for the treatment of viral infections G.D. Searle & Co. (US) 2001-08-22 EP disclosed
EP-1122245-A2 2-Amino-benzoxazinones for the treatment of viral infections G.D. Searle & Co. (US) 2001-08-08 EP disclosed
WO-2001053278-A1 2-THIO-4H-3,1-BENZOXAZIN-4-ONE DERIVATIVES FOR USE AS ENZYME INHIBITORS ALIZYME THERAPEUTICS LIMITED (GB) 2001-07-26 WO disclosed
US-5985872-A THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION G.D. SEARLE & CO. (US) 1999-11-16 US disclosed
WO-1998054192-A1 THIENOXAZINONE DERIVATIVES AS ANTIVIRAL AGENTS SMITHKLINE BEECHAM P.L.C. (GB) 1998-12-03 WO disclosed
WO-1998045298-A1 ANTIVIRAL AGENTS SMITHKLINE BEECHAM PLC (GB) 1998-10-15 WO disclosed
WO-1997048707-A1 4H-3,1-BENZOXAZIN-4-ONE DERIVATIVES AND ANALOGS AS ANTIVIRAL AGENTS SMITHKLINE BEECHAM PLC (GB) 1997-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, ACE2 MAOA 4035/4885MAOB 2526/4885HPGD 3672/4885
US-20060166957-A1 Methods of treating obesity and related disorders using tellurium selenium compounds SELENOI, AS3MT, SLC5A1 MAOA 2678/4885MAOB 2719/4885HPGD 4787/4885
US-20030013707-A1 2-amino-benzoxazinone derivatives for the treatment of obesity CYP4X1, CYP2B6, BBOX1 MAOA 160/4885MAOB 138/4885HPGD 1023/4885
US-20050032795-A1 2-Amino-benzoxazinones for the treatment of herpes simplex virus GABBR1, GABBR2, EBNA1BP2 MAOA 1832/4885MAOB 888/4885HPGD 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.